Adult hippocampal neurogenesis, Rho kinase inhibition and enhancement of neuronal survival.

Adult neurogenesis occurs throughout life; however the majority of new neurons do not survive. Enhancing the survival of these new neurons will increase the likelihood that these neurons could return function following injury. Inhibition of Rho kinase is known to increase neurite outgrowth and regeneration. Previous work in our lab has demonstrated a role for Rho kinase inhibition and survival of new born neurons from the sub-ventricular zone. In this study we examined the role of Rho kinase inhibition on hippocampal neurogenesis. Two concentrations of Rho kinase inhibitor Y27632 (20 and 100 µM) and the proliferative marker EdU were infused in the lateral ventricle for 7 days. Quantification of doublecortin+/EdU+ cells on the 7th day showed that cell numbers were not significantly different, suggesting no effect on neuroblast generation. Following infusion of 100µM Y27632, the number of newborn NeuN+/EdU+ neurons at 35 days in the granular cell layer of the dentate gyrus of the ipsilateral side of the infusion did not display a significant difference; however there was an increase on the contralateral side, suggesting a dose effect. Infusion of a lower dose (20 µM) of Y27632 resulted in an increase in NeuN+/EdU+ cells in the granular cell layer of the ipsilateral side at 35 days. These mice also demonstrated enhanced spatial memory as tested by the Y maze with no significant changes in anxiety or novel object recognition. Rho kinase inhibition enhanced the survival of new born neurons in the dentate gyrus with a specific dosage effect. These results suggest that inhibition of Rho kinase following injury could be beneficial for increasing the survival of new neurons that may aid recovery.

Peripheral axon regrowth: new molecular approaches.

Peripheral nerves, essential connections between the brain, spinal cord and body, do not regenerate as well as generally reported. Identifying new strategies to facilitate regeneration is essential to reversing neurological deficits from nerve injuries or disease. This review will discuss several selected and novel molecular insights into peripheral nerve trunk repair and axon regrowth that have the potential to improve regenerative success. Of particular interest is the phosphatidylinositol 3-kinase (PI3K)-Akt pathway in peripheral neurons, inhibited by the constitutively expressed phosphatase tumor suppressor PTEN. Knockdown or inhibition of PTEN is associated with robust sprouting of adult sensory neurons in vitro and in vivo, additive to the accelerated outgrowth offered by the preconditioning effect. This sprouting response, if spatially and temporally constrained, may provide potent regrowth initiation, of interest in otherwise untreatable nerve damage.

Modulation of locomotor activity by multiple 5-HT and dopaminergic receptor subtypes in the neonatal mouse spinal cord.

Recently, it has been shown that bath-applied 5-HT can elicit fictive locomotion from perinatal mouse preparations. Since 5-HT acts on multiple receptor subtypes, the focus of this study was to examine which receptor families contribute to the genesis and modulation of locomotor activity. Blockade of 5-HT(2) (ketanserin or N-desmethylclozapine) or 5-HT(7) receptors (SB-269970) could reversibly block or modulate the locomotor-like pattern. A 5-HT(2) agonist (alpha-methyl-5-HT) was shown to be capable of activating the rhythm. Bath application of 5-HT(7) agonists (5-CT) generally led to a tonic increase in neurogram discharge, accompanied by bouts of rhythmic activity. Blockade of dopaminergic receptors (D(1) [R-(+)-SCH-23390 or LE 300]/D(2) [(+/-)-sulpiride or L-741,626] ) could reversibly disrupt the rhythm and most effectively did so when the D(1) and D(2) antagonists were added together. Conversely, 5-HT(2) and D(1)/D(2) agonists can interact to evoke locomotor activity. Overall, our data show that, in the neonatal mouse preparation, 5-HT evoked locomotion is partly dependent on activation of 5-HT(2), 5-HT(7), and dopaminergic receptor subtypes.